Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies	B-cell neoplasm, Blood Protein Disorders, Burkitt lymphoma, CD4+/CD56+ hematodermic neoplasm, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, T-lymphoblastic lymphoma, Tumor Virus Infections, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, mature T-cell and NK-cell non-Hodgkin lymphoma, monoclonal gammopathy, myeloid leukemia, neoplasm, plasma cell leukemia, plasma cell neoplasm, skin disorder, skin neoplasm, vascular disorder, vascular hemostatic disease, viral infectious disease	Recruiting	Phase 1 / Phase 2	2026-04-13		NCT07523555

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Biotech	32

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Peking University Shenzhen Hospital	Shenzhen	China	68